drugset / Trial / NCT01069809

Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption

NCT01069809

Phase 2 Completed 53 enrolled Argos Therapeutics
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine the safety and effectiveness of AGS-004, an immune therapy, for HIV-infected individuals. Safety and effectiveness will be tested while the individuals are both taking antiretroviral therapy (ART) medication and interrupting ART medication.

Timeline

Start
2010-07
Primary completion
2014-08
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject AGS-004 Cell therapy